-

Fresenius Kabi Receives Premier Supplier Legacy Award

Premier Recognizes Fresenius Kabi USA for Operational Excellence

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received a 2021 Supplier Legacy Award from Premier Inc. (www.premierinc.com), a leading health care improvement company.

Fresenius Kabi was recognized for “its long-standing support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to cost optimizations,” according to Premier.

“Fresenius Kabi’s purpose is ‘caring for life’ - to put lifesaving medicines and technologies in the hands of people who care for patients and to find solutions to the challenges they face. Our employees' focus is on delivering the support needed by physicians, nurses, patients, hospitals and other sites of care, today and in the future. That’s why it’s particularly gratifying to receive this recognition from Premier,” said John Ducker, president and CEO of Fresenius Kabi USA.

Legacy Award winners have a tenure of more than three years as a Premier contracted supplier.

“Fresenius Kabi supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies,” said David A. Hargraves, Senior Vice President, Supply Chain, Premier. “We’re honored to recognize them as a Legacy Award recipient.”

Premier Inc. is a health care improvement company uniting an alliance of approximately 4,100 U.S. hospitals and health systems and more than 200,000 other providers and organizations. Premier has been named one of the World’s Most Ethical Companies® 13 years in a row.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit https://www.fresenius-kabi.com/us/join-us. To learn how the company is doing More in America, please visit https://www.fresenius-kabi.com/us/company/more-in-america.

Contacts

Media contact
Matt Kuhn, (847) 550-5751
matt.kuhn@fresenius-kabi.com

Industry:

Fresenius Kabi

Release Versions
English

Contacts

Media contact
Matt Kuhn, (847) 550-5751
matt.kuhn@fresenius-kabi.com

More News From Fresenius Kabi

Fresenius Kabi and Phlow Corp. Announce First-Ever, End-to-End, U.S. Manufacturing Collaboration for Epinephrine Injection, USP

LAKE ZURICH, Ill. & RICHMOND, Va.--(BUSINESS WIRE)--Fresenius Kabi and Phlow Corp. announced today a first-of-its-kind collaboration to onshore the manufacture of Epinephrine Injection, USP, an essential medicine long at risk of chronic shortage in the U.S. and widely used in hospitals nationwide. The arrangement, which includes the domestic manufacture of active pharmaceutical ingredients (APIs) and finished doses, is designed to be scalable to other essential medicines. Under the agreement, P...

Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has been certified by the Top Employers Institute as a 2026 Top Employer in the United States and North America. This affirms the company’s ongoing commitment to creating a positive work environment. Globally, Fresenius Kabi was certified as a Top Employer for 2026 in 13 countries and two regions. Since 2023, Fre...

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing. Frese...
Back to Newsroom